Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Aug 10;37(23):2092-2093.
doi: 10.1200/JCO.19.01078. Epub 2019 Jun 28.

Reply to E. Hindié et al

Roisin M Connolly  1 , Chiung-Yu Huang  1 , Vered Stearns  1 , Richard L Wahl  1
Affiliations
Comment

Reply to E. Hindié et al

Roisin M Connolly et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Hindié E, Groheux D.Interim [18F]fluorodeoxyglucose–positron emission tomography during neoadjuvant therapy in human epidermal growth factor receptor 2–positive breast cancer J Clin Oncol 37:2091-20922019 - PubMed
    1. Connolly RM, Leal JP, Solnes L, et al. TBCRC026: Phase II trial correlating standardized uptake value with pathologic complete response to pertuzumab and trastuzumab in breast cancer. J Clin Oncol. 2019;37:714–722. - PMC - PubMed
    1. Connolly RM, Leal JP, Goetz MP, et al. TBCRC 008: Early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med. 2015;56:31–37. - PMC - PubMed
    1. Gebhart G, Gamez C, Holmes E, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. J Nucl Med. 2013;54:1862–1868. - PubMed
    1. Coudert B, Pierga JY, Mouret-Reynier MA, et al. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted nonresponders (AVATAXHER): An open-label, randomised phase 2 trial. Lancet Oncol. 2014;15:1493–1502. - PubMed